Background
The most common cause of esophagitis is gastroesophageal reflux disease (GERD). (See Epidemiology.) Other important, but less common, types of esophagitis include infectious esophagitis (in patients who are immunocompromised), radiation esophagitis, and esophagitis from direct erosive effects of ingested medication or corrosive agents (see the image below). (See Pathophysiology.)
Go to Pediatric Esophagitis for complete information on this topic.
Corrosive esophagitis. This is a vinegar-induced esophageal burn. The patient had a fish bone in her throat. She ingested vinegar in an attempt to dissolve the fish bone but to no avail; this led to corrosive esophagitis. Eosinophilic esophagitis has also emerged as an important cause of esophagitis in both children and adults. Other causes of esophagitis include systemic disease and trauma. (See Etiology.)
The prognosis is good with rapid diagnosis and proper treatment. Ultimately, prognosis depends on the underlying disease process. (See Prognosis.)
The history findings vary based on the type of esophagitis (eg, reflux or infectious). The physical examination usually is not helpful in confirming the diagnosis of uncomplicated esophagitis. However, the examination may reveal other potential sources of chest or abdominal pain. (See Clinical Presentation.)
Laboratory tests are usually unhelpful unless complications are present (eg, upper GI hemorrhage). Routine radiography is not indicated unless complications (eg, perforation, obstruction, bleeding) are suspected. Double-contrast esophageal barium studies and upper endoscopy are the recommended initial imaging studies; these tests should be viewed as complementary rather than competing in the evaluation of patients with dysphagia. (See Workup.)
Treatment begins with hemodynamic stabilization and pain management. Subsequent therapy depends on the cause of the esophagitis and on any complications present.[1] Surgery (fundoplication) is sometimes indicated in patients with severe pain who fail to respond to medical management. (See Treatment and Management and Medications.)
Pathophysiology
The pathophysiology of esophagitis depends on its etiology (see Etiology, below). Common forms of esophagitis include reflux esophagitis, infectious esophagitis, pill esophagitis, eosinophilic esophagitis, and radiation and chemoradiation esophagitis.
Reflux esophagitis
Reflux esophagitis develops when gastric contents are passively regurgitated into the esophagus. Reflux happens commonly; in most cases, it does not cause major harm, because natural peristalsis of the esophagus clears the refluxate back to the stomach. In other cases, where acid reflux from the stomach is persistent, the result is damage to the esophagus, causing symptoms and macroscopic changes. Gastric acid, pepsin, and bile irritate the squamous epithelium, leading to inflammation, erosion, and ulceration of the esophageal mucosa.
Infectious esophagitis
Infectious esophagitis is most commonly observed in immunosuppressed hosts but has also been reported in healthy adults and children. A wide range of abnormalities in host defense may predispose an individual to opportunistic infections, such as neutropenia, impaired chemotaxis and phagocytosis, alteration in humoral immunity, and impaired T-cell lymphocyte function.
Patients with systemic diseases (eg, diabetes mellitus, adrenal dysfunction, alcoholism) and those of advanced age can be predisposed to infectious esophagitis because of altered immune function. Steroids, cytotoxic agents, radiation, and immune modulators can also contribute to impaired host immune function. Disruption of mucosal protective barriers and antibiotics that suppress the normal bacterial flora may contribute to the invasive ability of commensal organisms.[2]
Common types of infectious esophagitis include the following:
- Fungal (eg, Candida) esophagitis
- Viral (eg, herpes) esophagitis
- Tuberculous esophagitis
Candida esophagitis results from fungal overgrowth in the esophagus, impaired cell-mediated immunity, or both.
Fungal overgrowth typically occurs in the setting of esophageal stasis resulting from abnormal esophageal motility (eg, achalasia or scleroderma) or mechanical causes (eg, strictures). Impaired cell-mediated immunity can result from immunosuppressive therapy (eg, with steroids or cytotoxic agents, which may suppress both lymphocyte function and granulocyte function), malignancy, or AIDS. Chronic mucocutaneous candidiasis is a congenital immunodeficiency state that is also associated with Candida esophagitis.
Illnesses that interfere with esophageal peristalsis, such as achalasia, progressive systemic sclerosis, and esophageal neoplasias, may contribute to fungal esophagitis.
Initially, herpes esophagitis is manifested by the development of small vesicles that subsequently rupture to form discrete superficial ulcers on the mucosa. In immunocompetent patients, the host response promotes healing of the ulcers, but in patients who are severely immunocompromised, the condition may progress from discrete areas of ulceration to a diffuse hemorrhagic esophagitis. Necrotic herpetic ulcers may become superinfected by candidiasis.
In tuberculous esophagitis, the esophagus is usually involved by erosion of the involved mediastinal lymph nodes abutting the esophagus.
Go to Cytomegalovirus Esophagitis for complete information on this topic.
Medication-induced esophagitis (pill esophagitis)
Medications associated with pill esophagitis cause injury by local or topical injury.[3] Antibiotics, potassium chloride, nonsteroidal anti-inflammatory drugs (NSAIDs), quinidine, emperonium bromide, and alendronate (Fosamax) account for 90% of the reported cases. The following are important pill and patient factors:
- Chemical nature of drug
- Solubility
- Contact time with mucosa
- Size, shape, and pill coating
- Amount of water (ie, too little) taken to swallow pill (eg, alendronate)
- Preexisting esophageal pathology (eg, stricture, achalasia)
Eosinophilic esophagitis
The mechanism of eosinophilic esophagitis remains to be elucidated. However, a corrugated esophagus characterized by fine concentric mucosal rings is commonly observed in patients and is believed to be related to histamine released from sensitized mast cells in the esophageal wall. The release of histamine activates a cascade of reactions, culminating in acetylcholine release that contracts muscle fibers in the muscularis mucosae, resulting in the formation of concentric esophageal rings.[4, 5]
This hypothesis can be tested by performing endoscopic ultrasonography, which will reveal contraction of the muscle layers of the muscularis mucosae and may be related to immunoglobulin E (IgE) activation.
Radiation and chemoradiation esophagitis
Radiation therapy over 30 Gy to the mediastinum typically causes retrosternal burning and painful swallowing, which is usually mild and limited to the duration of therapy.[6]
- A dose of 40 Gy causes mucosal redness and edema.
- A dose of 50 Gy causes a higher incidence and severity of esophageal damage.
- A dose of 60-70 Gy causes moderate-to-severe esophagitis with strictures, perforations, and fistulas.
Etiology
The various types of esophagitis are associated with differing causative conditions and risk factors.
Reflux esophagitis
Factors or conditions that may increase the risk of reflux esophagitis include the following:
- Pregnancy
- Obesity
- Scleroderma
- Smoking
- Alcohol, coffee, chocolate, fatty or spicy foods
- Certain medications (eg, beta-blockers, NSAIDs, theophylline, nitrates, alendronate, calcium channel blockers)
- Mental retardation requiring institutionalization
- Spinal cord injury
- Immunocompromise
- Radiation therapy for chest tumors
- Pill esophagitis is thought to be secondary to chemical irritation of esophageal mucosa from certain medications (eg, iron, potassium, quinidine, aspirin, steroids, tetracyclines, NSAIDs), especially when medications are swallowed with too little fluid
- Helicobacter pylori eradication therapy has been inversely related to reflux esophagitis; it is postulated that the ammonia (alkaline) produced by H pylori reduces the acidity of the stomach and, hence, protects the esophagus from acid spillage
Infectious esophagitis
Infectious agents known to cause esophagitis include the following:
- Candida species: Candida albicans is the most common offending pathogen, but other Candida species, such as Candida tropicalis, Candida glabrata, and Candida parapsilosis, have also been implicated as rare causes of esophagitis
- Noncandidal fungi (eg, Aspergillus, Histoplasma, Cryptococcus, Blastomyces)
- Herpes simplex virus (HSV)
- Cytomegalovirus (CMV)
- Varicella-zoster virus (VZV)
- Epstein-Barr virus (EBV)
- In HIV -infected hosts, CMV, HSV, Mycobacterium avium-intracellulare, idiopathic
- Human papillomavirus (HPV)[7]
- Bacterial species (eg, normal flora, Mycobacterium tuberculosis, M. avium-intracellulare, Staphylococcus, Streptococcus, Lactobacillus, Nocardia)
- Parasitic infections (eg, Chagas disease, Trypanosoma cruzi, Cryptosporidium, Pneumocystis, Leishmania donovani)
Major predisposing factors for Candida esophagitis include antibiotic use, radiation therapy or chemotherapy, hematologic malignancies, and AIDS. Other conditions associated with an increased incidence of Candida esophagitis include esophageal stasis, alcoholism, malnutrition, and advanced age. Occasionally, Candida esophagitis can occur in otherwise healthy individuals with no underlying esophageal or systemic disease.[8, 9, 10, 11, 12, 13, 14]
Other infections of the esophagus are rare and most often develop in patients with neutropenia, AIDS, burns, trauma, or generalized sepsis. Actinomycosis may produce severe esophagitis with deep ulcers and fistulous tracts to the mediastinum, pleural space, tracheobronchial tree, and skin. The diagnosis can be confirmed by the presence of characteristic sulfur granules on endoscopic biopsy specimens.
In persons with HIV, the most significant risk factor for infectious esophagitis is a persistently low CD4 count, but reports exist of individuals who develop fungal esophagitis during the seroconversion phase.
Esophagitis associated with systemic illnesses
Systemic illnesses that can result in esophagitis include the following:
- Skin disorders, including epidermolysis bullosa, pemphigus vulgaris, bullous pemphigoid, cicatricial pemphigoid, drug-induced skin disorders (eg, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), and others (eg, lichen planus, psoriasis, acanthosis nigricans, leukoplakia)
- Eosinophilic esophagitis
- Graft versus host disease (GVHD)
- Chronic granulomatous disease
- Metastatic cancer
- Collagen vascular disease. Motility disorders of the esophagus lead to poor acid clearing, with resulting epithelial damage (ie, gastroesophageal reflux disease [GERD] in scleroderma)
Esophagitis associated with pharmacologic or other therapy
Therapeutic interventions that can cause esophagitis include the following:
- Medications (eg, pill esophagitis), including alendronate, antibiotics (eg, tetracycline), potassium, NSAIDs, quinidine, and chemotherapeutic agents (eg, dactinomycin, bleomycin, cytarabine, daunorubicin, 5-fluorouracil, methotrexate, vincristine)
- Radiation esophagitis may occur with radiation treatment of cancers located in the chest (ie, lung, esophagus, mediastinum)
- Sclerosant and band ligation therapy for varices can cause necrosis of esophageal tissues and mucosal ulcers; incidence and severity are higher with sclerosant therapy; later, strictures can develop
Epidemiology
Esophagitis is commonly seen in adults and is uncommon in childhood.[15, 16] The most common type of esophagitis is that associated with GERD (ie, reflux esophagitis). Candida esophagitis is the most common type of infectious esophagitis. Esophageal reflux symptoms occur monthly in 33-44% of the general population; up to 7-10% of people have daily symptoms.
International statistics
The incidence of symptoms of reflux is up to an order of magnitude higher than the prevalence of esophagitis. In the United Kingdom, patients presenting to a general practitioner with symptoms of reflux esophagitis show rates in the 40-65% range. However, a retrospective review of the results of more than 8000 diagnostic endoscopies in Hampshire showed that GERD accounted for 23% of all upper GI conditions.[17]
A review of the Swedish National Register estimated the prevalence of esophagitis (diagnosed by endoscopy) to be less than 5% in the 55-year-old group. Other reports have estimated the prevalence to be on the order of 2%.
Prevalence associated with other disorders
The prevalence of symptomatic infectious esophagitis is high in individuals with AIDS, leukemia, and lymphoma and is low (< 5%) in the general medical population.
Candida esophagitis is the most common type of infectious esophagitis. Herpes simplex virus type I is the second most common cause of infectious esophagitis . Although obtaining accurate figures regarding the prevalence of herpes esophagitis is difficult, this infection has been reported in approximately 1% of patients who are immunocompromised and in as many as 43% of patients at autopsy.[18, 19, 20, 21, 22, 23]
CMV is a recently recognized cause of esophagitis. Asymptomatic CMV infection is common worldwide, and a large percentage of the world’s population has been exposed to CMV. Before the AIDS epidemic, CMV infections of the esophagus were primarily found on postmortem examinations. The first clinical case of CMV esophagitis was not reported until 1985.
Unlike herpes esophagitis, CMV esophagitis almost never occurs in immunocompetent patients, and the vast majority of affected individuals are found to have AIDS. The incidence of CMV esophagitis—like that of other forms of infectious esophagitis—has declined among AIDS patients since the widespread use of highly active antiretroviral therapy.[24] However, CMV esophagitis has increased among patients with solid organ transplants,[25] in whom delayed-onset disease is typical because of increasing routine use of early CMV prophylaxis.[26]
Giant esophageal ulcers have been described in patients with AIDS in whom no other infectious etiology for the ulcers can be found. These ulcers have been termed idiopathic or HIV ulcers because they are believed to be caused by HIV. In fact, results of electron microscopy confirm the presence of HIV-like viral particles in these lesions.
Although some patients with HIV ulcers may have undergone recent seroconversion, most are found to have chronic AIDS with CD4 counts of less than 100 cells per cubic millimeter. HIV ulcers are more common than generally recognized, accounting for as many as 40% of all esophageal ulcers in patients with AIDS.[12, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36]
Prognosis
The prognosis is good with rapid diagnosis and proper treatment. Ultimately, prognosis depends on the underlying disease process.
Minimal morbidity and mortality result from mild symptoms of esophagitis. Pain from moderate-to-severe symptoms may produce anxiety and lost work and may lead to medical evaluations for more serious causes of pain.
Complicated esophagitis may lead to esophageal strictures (typically long, smooth, tapered areas of narrowing), malnutrition, and, rarely, perforation or bleeding. In addition to strictures, serious GI complications of esophagitis include Barrett esophagus and adenocarcinoma. Aspiration of gastric contents is a potentially serious respiratory complication that occurs more often in children. It may be associated with bronchospasm, pneumonitis, and apnea.
Severe esophagitis may lead to dysphagia, pain, odynophagia, and malnutrition. Rarely, life-threatening bleeding occurs and may lead to death. Outcomes and survival in these patients are related to the severity of their underlying systemic illness.
Recurrence is a frequent problem in patients with reflux. Many patients require maintenance therapy for relapse of symptoms.
Infectious esophagitis
Candida esophagitis is usually self-limiting, and most patients have a marked response to treatment with antifungal agents. However, necrotic mucosal debris and fungal mycelia in the esophagus occasionally form a mycetoma (ie, fungus ball) that causes obstruction. In other patients, severe Candida esophagitis may lead to development of strictures. Other complications include ulceration and hemorrhage and, rarely, fistula formation into the bronchial tree.[37]
In immunocompetent patients, herpes esophagitis often resolves spontaneously within 1-2 weeks with conservative treatment involving analgesia and sedation. Rare complications of herpes esophagitis include perforation, tracheoesophageal fistulas, and dissemination to other organs.
Patient Education
Lifestyle changes recommended to reduce the frequency and amount of gastric contents that may reflux back into the esophagus include the following:
- Elevate the head of the bed with 6-inch blocks (sleeping on extra pillows is discouraged because this actually may increase reflux by increasing intra-abdominal pressure caused by the patient bending at the waist)
- Stand upright for several hours after meals.
- Reduce meal size
- Lose weight
- Quit smoking
- Avoid alcohol and caffeine
- Avoid citrus, spicy or fatty foods, and chocolate
- Avoid aggravating medications such as aspirin and other over-the-counter NSAIDs
Educate patients on the disease process and the importance of early medical evaluation at the onset of symptoms.
To prevent pill esophagitis, instruct patients to take medications with plenty of water while sitting upright. Avoid certain medications (eg, alendronate) in patients with known esophageal varices. Alendronate in patients who are cirrhotic could precipitate GI bleeding from erosions over an esophageal varix.
For patient education information, see the Heartburn/GERD/Reflux Center and Esophagus, Stomach, and Intestine Center, as well as Reflux Disease (GERD), Heartburn, and Understanding Heartburn/GERD Medications.
Lowe RC, Wolfe MM. The pharmacological management of gastroesophageal reflux disease. Minerva Gastroenterol Dietol. Sep 2004;50(3):227-37. [Medline].
Rothenberg ME. Biology and treatment of eosinophilic esophagitis. Gastroenterology. Oct 2009;137(4):1238-49. [Medline].
Winstead NS, Bulat R. Pill Esophagitis. Curr Treat Options Gastroenterol. Feb 2004;7(1):71-76. [Medline].
Liacouras CA, Ruchelli E. Eosinophilic esophagitis. Curr Opin Pediatr. Oct 2004;16(5):560-6. [Medline].
Mann NS, Leung JW. Pathogenesis of esophageal rings in eosinophilic esophagitis. Med Hypotheses. 2005;64(3):520-3. [Medline].
Bradley J, Movsas B. Radiation esophagitis: Predictive factors and preventive strategies. Semin Radiat Oncol. Oct 2004;14(4):280-6. [Medline].
Quarto G, Sivero L, Somma P, De Rosa G, Mosella F, Nunziata G, et al. A case of infectious esophagitis caused by human papilloma virus. Minerva Gastroenterol Dietol. Sep 2008;54(3):317-21. [Medline].
Haron E, Vartivarian S, Anaissie E, Dekmezian R, Bodey GP. Primary Candida pneumonia. Experience at a large cancer center and review of the literature. Medicine (Baltimore). May 1993;72(3):137-42. [Medline].
Levine MS, Macones AJ Jr, Laufer I. Candida esophagitis: accuracy of radiographic diagnosis. Radiology. Mar 1985;154(3):581-7. [Medline].
Walsh TJ, Hamilton SR, Belitsos N. Esophageal candidiasis. Managing an increasingly prevalent infection. Postgrad Med. Aug 1988;84(2):193-6, 201-5. [Medline].
Kliemann DA, Pasqualotto AC, Falavigna M, Giaretta T, Severo LC. Candida esophagitis: species distribution and risk factors for infection. Rev Inst Med Trop Sao Paulo. Sep-Oct 2008;50(5):261-3. [Medline].
Vidal AP, Pannain VL, Bottino AM. [Esophagitis in patients with acquired human immunodeficiency syndrome: an histological and immunohistochemistry study]. Arq Gastroenterol. Oct-Dec 2007;44(4):309-14. [Medline].
Bianchi Porro G, Parente F, Cernuschi M. The diagnosis of esophageal candidiasis in patients with acquired immune deficiency syndrome: is endoscopy always necessary?. Am J Gastroenterol. Feb 1989;84(2):143-6. [Medline].
Sam JW, Levine MS, Rubesin SE, Laufer I. The "foamy" esophagus: a radiographic sign of Candida esophagitis. AJR Am J Roentgenol. Apr 2000;174(4):999-1002. [Medline].
Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. Oct 2009;7(10):1055-61. [Medline].
Nurko S, Rosen R, Furuta GT. Esophageal dysmotility in children with eosinophilic esophagitis: a study using prolonged esophageal manometry. Am J Gastroenterol. Dec 2009;104(12):3050-7. [Medline].
McColl KE. Review article: Helicobacter pylori and gastro-oesophageal reflux disease--the European perspective. Aliment Pharmacol Ther. Dec 2004;20 Suppl 8:36-9. [Medline].
Chen LI, Chang JM, Kuo MC, Hwang SJ, Chen HC. Combined herpes viral and candidal esophagitis in a CAPD patient: case report and review of literature. Am J Med Sci. Mar 2007;333(3):191-3. [Medline].
DeGaeta L, Levine MS, Guglielmi GE, Raffensperger EC, Laufer I. Herpes esophagitis in an otherwise healthy patient. AJR Am J Roentgenol. Jun 1985;144(6):1205-6. [Medline].
Levine MS, Laufer I, Kressel HY, Friedman HM. Herpes esophagitis. AJR Am J Roentgenol. May 1981;136(5):863-6. [Medline].
Levine MS, Loevner LA, Saul SH, Rubesin SE, Herlinger H, Laufer I. Herpes esophagitis: sensitivity of double-contrast esophagography. AJR Am J Roentgenol. Jul 1988;151(1):57-62. [Medline].
Shortsleeve MJ, Levine MS. Herpes esophagitis in otherwise healthy patients: clinical and radiographic findings. Radiology. Mar 1992;182(3):859-61. [Medline].
Borowitz SM. Diagnosis: herpes simplex esophagitis. Clin Pediatr (Phila). Jul 2007;46(6):557-9. [Medline].
Geagea A, Cellier C. Scope of drug-induced, infectious and allergic esophageal injury. Curr Opin Gastroenterol. Jul 2008;24(4):496-501. [Medline].
Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr Gastroenterol Rep. Aug 2008;10(4):409-16. [Medline].
Buckner FS, Pomeroy C. Cytomegalovirus disease of the gastrointestinal tract in patients without AIDS. Clin Infect Dis. Oct 1993;17(4):644-56. [Medline].
Bonacini M, Young T, Laine L. Histopathology of human immunodeficiency virus-associated esophageal disease. Am J Gastroenterol. Apr 1993;88(4):549-51. [Medline].
Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med. Aug 1991;151(8):1567-72. [Medline].
Calore EE, Cavaliere JM, Perez NM, Campos Sales PS, Warnke KO. Esophageal ulcers in AIDS. Pathologica. Apr 1997;89(2):155-8. [Medline].
Edwards P, Wodak A, Cooper DA, Thompson IL, Penny R. The gastrointestinal manifestations of AIDS. Aust N Z J Med. Apr 1990;20(2):141-8. [Medline].
Levine MS, Loercher G, Katzka DA, Herlinger H, Rubesin SE, Laufer I. Giant, human immunodeficiency virus-related ulcers in the esophagus. Radiology. Aug 1991;180(2):323-6. [Medline].
Levine MS, Woldenberg R, Herlinger H, Laufer I. Opportunistic esophagitis in AIDS: radiographic diagnosis. Radiology. Dec 1987;165(3):815-20. [Medline].
Raufman JP. Infectious esophagitis in AIDS: what have we learned in the last decade?. Am J Gastroenterol. Nov 1995;90(11):1914-5. [Medline].
Sor S, Levine MS, Kowalski TE, Laufer I, Rubesin SE, Herlinger H. Giant ulcers of the esophagus in patients with human immunodeficiency virus: clinical, radiographic, and pathologic findings. Radiology. Feb 1995;194(2):447-51. [Medline].
Villanueva JL, Torre-Cisneros J, Jurado R, Villar A, Montero M, López F, et al. Leishmania esophagitis in an AIDS patient: an unusual form of visceral leishmaniasis. Am J Gastroenterol. Feb 1994;89(2):273-5. [Medline].
Yangco BG, Kenyon VS. Epidemiology and infectious complications of human immunodeficiency virus antibody positive patients. Adv Exp Med Biol. 1993;335:235-40. [Medline].
Mimidis K, Papadopoulos V, Margaritis V, Thomopoulos K, Gatopoulou A, Nikolopoulou V, et al. Predisposing factors and clinical symptoms in HIV-negative patients with Candida oesophagitis: are they always present?. Int J Clin Pract. Feb 2005;59(2):210-3. [Medline].
Dellon ES, Gibbs WB, Fritchie KJ, Rubinas TC, Wilson LA, Woosley JT, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol. Dec 2009;7(12):1305-13; quiz 1261. [Medline]. [Full Text].
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. Jan 2005;100(1):190-200. [Medline].
Amaro R, Poniecka AW, Goldberg RI. Herpes esophagitis. Gastrointest Endosc. Jan 2000;51(1):68. [Medline].
Howden CW, Hornung CA. A systematic review of the association between Barrett's esophagus and colon neoplasms. Am J Gastroenterol. Oct 1995;90(10):1814-9. [Medline].
Nonevski IT, Downs-Kelly E, Falk GW. Eosinophilic esophagitis: an increasingly recognized cause of dysphagia, food impaction, and refractory heartburn. Cleve Clin J Med. Sep 2008;75(9):623-6, 629-33. [Medline].
Wilheim AB, Miranda-Filho Dde B, Nogueira RA, Rêgo RS, Lima Kde M, Pereira LM. The resistance to fluconazole in patients with esophageal candidiasis. Arq Gastroenterol. Jan-Mar 2009;46(1):32-7. [Medline].
Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology. Nov 2010;139(5):1526-37, 1537.e1. [Medline].
Agency for Healthcare Research and Quality. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. AHRQ: Agency for Healthcare Research and Quality. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=1&DocID=42. Accessed January 30, 2009.
Donnellan C, Sharma N, Preston C, Moayyedi P. Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev. Apr 18 2005;CD003245. [Medline].
Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett's oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut. Jun 2005;54(6):746-51. [Medline]. [Full Text].
Medical Economics Staff. Physicians' Desk Reference. 55th ed. Medical Economics Company: Montvale, NJ; 2001.

